The Specialty Pharmaceuticals Pivot — RCA, Buy-and-Bill, and the Future of Drug Distribution

The single most important strategic story at Cencora today is the pivot from commodity drug wholesaling to specialty pharmaceuticals, capped by the $4.4 billion acquisition of Retina Consultants of America in January 2025. This module helps candidates understand vertical integration into physician practices, why specialty matters, and how to talk about it credibly in an interview.